- Home
- IKNA vs CTXR Comparison
IKNA vs CTXR Comparison
Compare IKNA & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- CTXR
- Stock Information
- Founded
- IKNA 2016
- CTXR 2007
- Country
- IKNA United States
- CTXR United States
- Employees
- IKNA N/A
- CTXR N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- CTXR Health Care
- Exchange
- IKNA Nasdaq
- CTXR Nasdaq
- Market Cap
- IKNA 74.8M
- CTXR 84.9M
- IPO Year
- IKNA 2021
- CTXR N/A
- Fundamental
- Price
- IKNA $1.57
- CTXR $3.31
- Analyst Decision
- IKNA Buy
- CTXR Buy
- Analyst Count
- IKNA 2
- CTXR 2
- Target Price
- IKNA $3.00
- CTXR $100.00
- AVG Volume (30 Days)
- IKNA 399.7K
- CTXR 151.2K
- Earning Date
- IKNA 11-07-2024
- CTXR 02-12-2025
- Dividend Yield
- IKNA N/A
- CTXR N/A
- EPS Growth
- IKNA N/A
- CTXR N/A
- EPS
- IKNA N/A
- CTXR N/A
- Revenue
- IKNA $659,000.00
- CTXR N/A
- Revenue This Year
- IKNA N/A
- CTXR N/A
- Revenue Next Year
- IKNA N/A
- CTXR N/A
- P/E Ratio
- IKNA N/A
- CTXR N/A
- Revenue Growth
- IKNA N/A
- CTXR N/A
- 52 Week Low
- IKNA $1.22
- CTXR $2.44
- 52 Week High
- IKNA $2.17
- CTXR $26.75
- Technical
- Relative Strength Index (RSI)
- IKNA 42.72
- CTXR 40.56
- Support Level
- IKNA $1.62
- CTXR $3.15
- Resistance Level
- IKNA $1.94
- CTXR $2.85
- Average True Range (ATR)
- IKNA 0.10
- CTXR 0.31
- MACD
- IKNA -0.01
- CTXR 0.26
- Stochastic Oscillator
- IKNA 16.85
- CTXR 69.60
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.